

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.** Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 17/097,285	Applicant(s) TARDIF, Jean-Claude	
	Examiner BRIAN J DAVIS	Art Unit 1612	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to inventor's RCE (3/21/2022).
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are See Continuation Sheet. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov**.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
Certified copies:
a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892) 2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>3/21/2022</u> . 3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____. 4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.	5. ☐ Examiner's Amendment/Comment 6. ☒ Examiner's Statement of Reasons for Allowance 7. ☐ Other _____.
---	--

/BRIAN J DAVIS/ Primary Examiner, Art Unit 1612	3/26/2022
--	-----------

Continuation of 3. The allowed claim(s) is/are: 1,3-26,28-52 [renumbered 1-50]

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/21/2022 has been entered.

102 Rejections Withdrawn

The rejection of claims 1, 3-8, 10, 14, 18, 19, 22, 25, 26 and 28 under 35 USC 102(a)(1), maintained in the previous Office Action, has been overcome by inventor's amendment. The amendment narrows the scope of the claim set such that it no longer reads on the cited art.

103 Rejections Withdrawn

The rejection of claims 13, 15-17 and 20 under 35 USC 103, maintained in the previous Office Action, has been overcome by inventor's amendment. The amendment narrows the scope of the claim set such that it no longer reads on the cited art.

Claim Objections Withdrawn

The objection to claims 2, 9, 11, 12, 21, 23 and 24, as being dependent upon a rejected base claim but otherwise allowable, is withdrawn. The objection is moot.

Allowable Subject Matter

Claims 1, 3-26 and 28-52 are allowed. The following is an examiner's statement of reasons for allowance:

With respect to claims 1, 3-8, 10, 13-20, 22, 25, 26 and 28, the closest prior art appears to be *American Heart Journal* (September 2019), Vol. 215, pp. 62-69 and *Circulation* (2015), 132(15), pp. 1395-1403, both cited in the IDS.

The 102 and 103 rejections of record in the instant application were predicated upon the *American Heart Journal* (September 2019), Vol. 215, pp. 62-69 reference, which has been outlined in detail in the previous Office Actions (and below). *Circulation* (2015), 132(15), pp. 1395-1403 is a clinical study which teaches treatment with colchicine for 5 days of acute myocardial infarction patients, who have also been treated with primary percutaneous coronary intervention (abstract). Significantly, the patients received a loading dose of 2 mg colchicine (1.5 mg initially followed by 0.5 mg 1 hour later), prior to 0.5 mg twice daily for 5 days, or with a placebo (page 1396, column 2, line 4).

As stated in the previous Office Action, *American Heart Journal* (September 2019), Vol. 215, pp. 62-69 teaches a method of treating adult human patients (>18 years old) after a myocardial infarction (MI) comprising administering low dose (0.5 mg once daily) colchicine within 7 days of the (MI) (abstract; page 63, column 1, **Methods**). The examiner notes for clarity of the record that the prior art teaching of administration within 7 days fully encompasses the instant teaching of within about 3 days of the MI. The reference is drawn to a pilot, randomized, double blind, placebo-controlled trial whose patients were recruited at Royal Perth Hospital, Perth Australia (abstract; page 63, column 1, **Methods**). The patients, in some cases, had been prescribed medications such as antiplatelet agents, aspirin, or a statin (page 65, Table 1). Patients administered colchicine were at a lower risk of a cardiovascular event, such as MI, relative to a patient not being administered colchicine (page 66, column 1, **Clinical outcomes, tolerability and safety**).

One of ordinary skill would not have found it obvious to treat the myocardial infarction patients of *Circulation* (2015), 132(15), pp. 1395-1403, who have also been treated with primary percutaneous coronary intervention, following the method of *American Heart Journal* (September 2019), Vol. 215, pp. 62-69 – that is, without a loading dose of colchicine. There is no motivation to delete the loading dose of *Circulation* (2015), 132(15), pp. 1395-1403 and treat these patients by the method of *American Heart Journal* (September 2019), Vol. 215, pp. 62-69.

With respect to claims 9, 11, 12, 21, 23, 24 and 42-52, the closest prior art appears to be *American Heart Journal* (September 2019), Vol. 215, pp. 62-69, outlined above. In particular, the reference does not teach show suggest or make obvious the

cardiovascular events: resuscitated cardiac arrest, stroke, or urgent hospitalization for angina requiring coronary revascularization.

With respect to claims 29-31, the closest prior art also appears to be *American Heart Journal* (September 2019), Vol. 215, pp. 62-69, outlined above. The reference does not teach, show, suggest or make obvious the instant method of reducing the risk of a stroke in a patient having had a myocardial infarction by the administration of daily low dose colchicine within about 30 days of the myocardial infarction.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fred Krass, can be reached at 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: <https://patentcenter.uspto.gov>. Visit <https://www.uspto.gov/patents/apply/patent-center> for more information about Patent Center and <https://www.uspto.gov/patents/docx> for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/BRIAN J DAVIS/
Primary Examiner, Art Unit 1612
3/26/2022

Issue Classification 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

CPC						
Symbol					Type	Version
A61K		31	/	165	F	2013-01-01
A61P	/	9	/	10	I	2018-01-01

CPC Combination Sets					
Symbol			Type	Set	Ranking

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	50	
/BRIAN J DAVIS/ Primary Examiner, Art Unit 1612	26 March 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	--

Issue Classification 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

INTERNATIONAL CLASSIFICATION			
CLAIMED			
A61K31/165		31	165
A61P9/10		9	10
NON-CLAIMED			

US ORIGINAL CLASSIFICATION	
CLASS	SUBCLASS

CROSS REFERENCES(S)						
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	50	
/BRIAN J DAVIS/ Primary Examiner, Art Unit 1612	26 March 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	--

U.S. Patent and Trademark Office

Part of Paper No.: 20220326

Issue Classification 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47															
CLAIMS															
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	1	9	10	18	19	26	28	35	37	44	46				
	2	10	11	19	20	27	29	36	38	45	47				
2	3	11	12	20	21	28	30	37	39	46	48				
3	4	12	13	21	22	29	31	38	40	47	49				
4	5	13	14	22	23	30	32	39	41	48	50				
5	6	14	15	23	24	31	33	40	42	49	51				
6	7	15	16	24	25	32	34	41	43	50	52				
7	8	16	17	25	26	33	35	42	44						
8	9	17	18		27	34	36	43	45						

NONE (Assistant Examiner) _____ (Date) _____		Total Claims Allowed: 50	
/BRIAN J DAVIS/ Primary Examiner, Art Unit 1612 (Primary Examiner) _____ (Date) 26 March 2022		O.G. Print Claim(s) 1	O.G. Print Figure --

U.S. Patent and Trademark Office

Part of Paper No.: 20220326

<i>Search Notes</i> 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

CPC - Searched*		
Symbol	Date	Examiner
A61K 31/165 (cursory, 4/2021 to date)	03/26/2022	/BJD/

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
Keyword searches in EAST (see search history printouts (3))	03/26/2022	/BJD/
Global Dossier	03/26/2022	/BJD/
Inventor name search in PE2E	03/26/2022	/BJD/


Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
A61K	31/165 (EAST, 4/2021 to date)	03/26/2022	/BJD/

/BRIAN J DAVIS/ Primary Examiner, Art Unit 1612	03/26/2022
--	------------

<i>Index of Claims</i> 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS										
☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47										
CLAIM		DATE								
Final	Original	01/11/2021	04/19/2021	03/26/2022						
1	1	✓	✓	=						
	2	○	○	-						
2	3	✓	✓	=						
3	4	✓	✓	=						
4	5	✓	✓	=						
5	6	✓	✓	=						
6	7	✓	✓	=						
7	8	✓	✓	=						
8	9	○	○	=						
9	10	✓	✓	=						
10	11	○	○	=						
11	12	○	○	=						
12	13	✓	✓	=						
13	14	✓	✓	=						
14	15	✓	✓	=						
15	16	✓	✓	=						
16	17	✓	✓	=						
17	18	✓	✓	=						
18	19	✓	✓	=						
19	20	✓	✓	=						
20	21	○	○	=						
21	22	✓	✓	=						
22	23	○	○	=						
23	24	○	○	=						
24	25	✓	✓	=						
25	26	✓	✓	=						
	27	✓	-	-						
26	28	✓	✓	=						
27	29	○	=	=						
28	30	○	=	=						
29	31			=						
30	32			=						
31	33			=						
32	34			=						
33	35			=						
34	36			=						
35	37			=						
36	38			=						
37	39			=						
38	40			=						
39	41			=						
40	42			=						

<i>Index of Claims</i> 	Application/Control No. 17/097,285	Applicant(s)/Patent Under Reexamination TARDIF, Jean-Claude
	Examiner BRIAN J DAVIS	Art Unit 1612

CLAIM		DATE								
Final	Original	01/11/2021	04/19/2021	03/26/2022						
41	43			=						
42	44			=						
43	45			=						
44	46			=						
45	47			=						
46	48			=						
47	49			=						
48	50			=						
49	51			=						
50	52			=						

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	42,480	colchicine	US-PGPUB; USPAT	OR	ON	2022/03/26 14:04
L2	94,455	low adj dose	US-PGPUB; USPAT	OR	ON	2022/03/26 14:04
L3	4,482	I1 and I2	US-PGPUB; USPAT	OR	ON	2022/03/26 14:05
L4	112,316	myocardial adj infarction	US-PGPUB; USPAT	OR	ON	2022/03/26 14:05
L5	1,267	I3 and I4	US-PGPUB; USPAT	OR	ON	2022/03/26 14:05
L6	125,648	percutaneous	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L7	126,008	stent	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L8	352	I5 and I6	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L9	433	I5 and I7	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L10	546	I8 or I9	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L11	788,023	daily	US-PGPUB; USPAT	OR	ON	2022/03/26 14:06
L12	354	I10 and I11	US-PGPUB; USPAT	OR	ON	2022/03/26 14:07

3/26/2022 2:14:22 PM

C:\Users\bdavis\Documents\EAST\Workspaces\~auto.07062018.040755.wsp

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	42,480	colchicine	US-PGPUB; USPAT	OR	ON	2022/03/26 14:15
L2	108,598	low adj dos\$5	US-PGPUB; USPAT	OR	ON	2022/03/26 14:16
L3	4,849	l1 and l2	US-PGPUB; USPAT	OR	ON	2022/03/26 14:16
L4	788,023	daily	US-PGPUB; USPAT	OR	ON	2022/03/26 14:16
L5	3,351	l3 and l4	US-PGPUB; USPAT	OR	ON	2022/03/26 14:17
L6	112,316	myocardial adj infarction	US-PGPUB; USPAT	OR	ON	2022/03/26 14:17
L7	954	l5 and l6	US-PGPUB; USPAT	OR	ON	2022/03/26 14:17
L8	1,957,387	\$10loading	US-PGPUB; USPAT	OR	ON	2022/03/26 14:17
L9	509	l7 and l8	US-PGPUB; USPAT	OR	ON	2022/03/26 14:18
L10	160,638	arrest	US-PGPUB; USPAT	OR	ON	2022/03/26 14:18
L11	660,747	stroke	US-PGPUB; USPAT	OR	ON	2022/03/26 14:18
L12	63,635	angina	US-PGPUB; USPAT	OR	ON	2022/03/26 14:19
L13	278	l9 and l10	US-PGPUB; USPAT	OR	ON	2022/03/26 14:19
L14	399	l9 and l11	US-PGPUB; USPAT	OR	ON	2022/03/26 14:19
L15	200	l9 and l12	US-PGPUB; USPAT	OR	ON	2022/03/26 14:19
L16	454	l13 or l14 or l15	US-PGPUB; USPAT	OR	ON	2022/03/26 14:19

3/26/2022 2:40:18 PM

C:\Users\bdavis\Documents\EAST\Workspaces\~auto.07062018.040755.wsp

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	42,480	colchicine	US-PGPUB; USPAT	OR	ON	2022/03/26 14:41
L2	112,316	myocardial adj infarction	US-PGPUB; USPAT	OR	ON	2022/03/26 14:41
L3	4,888	l1 and l2	US-PGPUB; USPAT	OR	ON	2022/03/26 14:41
L4	8,640	risk near stroke	US-PGPUB; USPAT	OR	ON	2022/03/26 14:42
L5	119	l3 and l4	US-PGPUB; USPAT	OR	ON	2022/03/26 14:42

3/26/2022 2:50:43 PM

C:\Users\bdavis\Documents\EAST\Workspaces\~auto.07062018.040755.wsp

Bibliographic Data

Application No: 17/097,285

Foreign Priority claimed: ☐ Yes ☒ No

35 USC 119 (a-d) conditions met: ☐ Yes ☒ No ☐ Met After Allowance

Verified and Acknowledged:

/BRIAN J DAVIS/

Examiner's Signature

Initials

Title:

EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE
AFTER MYOCARDIAL INFARCTION

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
11/13/2020	424	1612	50761-029001
RULE			

APPLICANTS

INSTITUT DE CARDIOLOGIE DE MONTREAL, Montreal, CANADA

INVENTORS

Jean-Claude TARDIF, Montreal, CANADA

CONTINUING DATA

This application has PRO of 63093988 10/20/2020

This application has PRO of 62935865 11/15/2019

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

11/24/2020

STATE OR COUNTRY

CANADA

ADDRESS

CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110
UNITED STATES

FILING FEE RECEIVED

\$7,160

PTO/SB/08b (07-09)

Approved for use through 07/31/2016. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	17/097,285
				Filing Date	November 13, 2020
				First Named Inventor	Jean-Claude TARDIF
				Art Unit	1612
				Examiner Name	B. J. Davis
Sheet	1	of	1	Attorney Docket Number	50761-029001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A	Office Action for Canadian Patent Application No. 3,099,143 mailed September 16, 2021 (4 pages).	

Examiner Signature	/BRIAN J DAVIS/	Date Considered	03/26/2022
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

IDS Filed March 21, 2022

17/097,285
/BJD/

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2,795	A61K31/165.cpc.	USPAT	OR	ON	2022/03/26 14:53

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	3,633	A61K31/165.cpc.	US-PGPUB	OR	ON	2022/03/26 14:55

3/26/2022 2:57:31 PM

C:\Users\bdavis\Documents\EAST\Workspaces\~auto.07062018.040755.wsp

To: patentadministrator@clarkelbing.com,smmichaud@clarkelbing.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 21559

Apr 05, 2022 04:21:48 AM

Dear PAIR Customer:

CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 21559 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
17097285	NOA	04/05/2022	50761-029001
	1449	04/05/2022	50761-029001

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/097,285	11/13/2020	Jean-Claude TARDIF	50761-029001	3015
21559 7590 04/26/2022 CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110			EXAMINER DAVIS, BRIAN J	
			ART UNIT 1612	PAPER NUMBER
			NOTIFICATION DATE 04/26/2022	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com
smmichaud@clarkelbing.com



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Application No. : 17097285
Applicant : Tardif
Filing Date : 11/13/2020
Date Mailed : 04/26/2022

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given two (2) months from the mail date of this Notice within which to respond. This time period for reply is extendable under 37 CFR 1.136(a) for only TWO additional MONTHS.

The informalities requiring correction are indicated in the attachment(s). If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to respond within the above-identified time period will result in the application being ABANDONED.

See attachment(s).

*A copy of this notice **MUST** be returned with the reply. Please address response to
"Mail Stop Issue Fee, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450".*

/Quang Nguyen/
Publication Branch
Office of Data Management
(571) 272-4200

IDENTIFICATION OF DRAWING DEFICIENCIES

- ☐ There is a hole or the image thereof within the illustration. FIG(s)
- ☐ The illustration is penetrated or traversed by a solid or broken line that is not intended to be part of the drawing, such as a dark line caused by a flaw in the copying process. FIG(s)
- ☐ An ink stamp or the image thereof obscures part of the illustration. FIG(s)
- ☐ The drawing is marred by black smudges, obliterations, or fax/copier marks (for example, speckles or dots in a substantial portion of the drawing). FIG(s)
- ☐ Figure numbers are duplicated or missing. FIG(s)
- ☐ Drawing sheet or figure is missing. FIG(s)
- ☐ Numbers, letters, or reference characters in the drawing have been crossed out or are illegibly handwritten. FIG(s)
- ☒ The character of the lines, numbers, and letters is poor. FIG(s) 3A-3B
- ☐ The drawing's background shows that the original drawing was made on graph paper or other paper with a pattern or decoration. FIG(s)
- ☐ The FIG. number label is placed in a location that causes the drawing to be read upside down. FIG(s)
- ☐ Data, a reference number, or part of the drawing is truncated or missing, or a lead line has no reference number. FIG(s)
- ☐ The drawing and/or the FIG. label contain(s) foreign language. FIG(s)
- ☐ This utility application contains a photograph of a view that is capable of being illustrated as a line drawing. FIG(s)
- ☐ A petition under 37 CFR 1.84(a)(2) to accept color drawings has been granted, but the brief description of the drawings in the specification does not contain (or has not been amended to contain) the paragraph required by 37 CFR 1.84(a)(2)(iii).
- ☐ This reissue application contains added and/or amended drawings that are not labeled as "New" or "Amended" or "Canceled" as required by 37 CFR 1.173(b)(3). FIG(s)
- ☐ This Design reissue application contains a drawing that is labeled as "Canceled" but is not surrounded by brackets, or a drawing that is surrounded by brackets but is not labeled as "Canceled." See 37 CFR 1.173(b)(3). FIG(s)
- ☐ OTHER:
- ☐ COMMENTS:

Docket No.: 50761-029001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Utility Application of:
Jean-Claude TARDIF

Application No.: 17/097,285

Confirmation No.: 3015

Filed: November 13, 2020

Art Unit: 1612

For: EARLY ADMINISTRATION OF LOW-DOSE
COLCHICINE AFTER MYOCARDIAL INFARCTION

Examiner: B. J. Davis

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

In response to the Notice to File Corrected Application Papers mailed April 26, 2022, Applicant respectfully submits the following remarks.

Electronic Acknowledgement Receipt	
EFS ID:	45561276
Application Number:	17097285
International Application Number:	
Confirmation Number:	3015
Title of Invention:	EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
First Named Inventor/Applicant Name:	Jean-Claude TARDIF
Customer Number:	21559
Filer:	Jan Tittel/Elicia Niland
Filer Authorized By:	Jan Tittel
Attorney Docket Number:	50761-029001
Receipt Date:	26-APR-2022
Filing Date:	13-NOV-2020
Time Stamp:	12:22:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----


File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Drawings-only black and white line drawings	Replacement_Sheet.PDF	199540	no	1
			93de42b2045ef630695ec0204b48b8451356bb3c		

Warnings:


Information:					
2		Reply.pdf	132855	yes	6
			32a2bb64361b2d1648a007547e9bd9cab77699eb		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Applicant Response to Pre-Exam Formalities Notice		1	1	
	Specification		2	2	
	Applicant Arguments/Remarks Made in an Amendment		3	6	
Warnings:					
Information:					
Total Files Size (in bytes):			332395		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

FIG. 3A



No. at Risk	604	586	477	313	157	29	0
Colchicine	589	554	432	290	149	28	0
Placebo							

FIG. 3B



No. at Risk	604	587	480	316	159	30	0
Colchicine	589	561	438	296	153	29	0
Placebo							

To: patentadministrator@clarkelbing.com,smmichaud@clarkelbing.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 21559

Apr 26, 2022 05:01:39 AM

Dear PAIR Customer:

CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 21559 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
17097285	M327	04/26/2022	50761-029001

To view your correspondence online or update your email addresses, please visit us anytime at <https://portal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

PART B—FEE(S) TRANSMITTAL

Complete and send this form, together with the applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By fax, send to: (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

21559
CLARK & ELBING LLP
101 Federal Street
15th Floor
Boston, MA 02110

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
17/097,285	11/13/2020	Jean-Claude TARDIF	50761-029001	3015

TITLE OF INVENTION: EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION

APPLN: TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1,200.00			\$1,200.00	07/05/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
B. J. Davis	1612	424/474000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363) ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. Use of a Customer Number is required.	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.	1. Clark & Elbing LLP 2. 3.
---	---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY AND STATE or COUNTRY)

INSTITUT DE CARDIOLOGIE DE MONTREAL

Montreal, Canada

Please check the appropriate assignee category or categories (will not be printed on the patent):

☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. Fees Submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment (Please first reapply any previously paid fee shown above):

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 03-2095

5. Change of Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29.

NOTE: Absent a valid Certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

☐ Applicant asserting small entity status. See 37 CFR 1.27.

NOTE: If the application was previously under micro entity status, checking this box will be taken as a notification of loss of entitlement to micro entity status.

☐ Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken as a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature

/Jan N. Tittel/

Date April 27, 2022

Typed or printed name

Jan N. Tittel, Ph.D.

Registration No.

52,290

Electronic Patent Application Fee Transmittal				
Application Number:		17097285		
Filing Date:		13-Nov-2020		
Title of Invention:		EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION		
First Named Inventor/Applicant Name:		Jean-Claude TARDIF		
Filer:		Jan Tittel/Ashley Lombardi		
Attorney Docket Number:		50761-029001		
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	1501	1	1200	1200

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1200

Electronic Acknowledgement Receipt	
EFS ID:	45571025
Application Number:	17097285
International Application Number:	
Confirmation Number:	3015
Title of Invention:	EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
First Named Inventor/Applicant Name:	Jean-Claude TARDIF
Customer Number:	21559
Filer:	Jan Tittel/Cristina Lofton
Filer Authorized By:	Jan Tittel
Attorney Docket Number:	50761-029001
Receipt Date:	27-APR-2022
Filing Date:	13-NOV-2020
Time Stamp:	10:30:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$1200
RAM confirmation Number	E20224QA30490276
Deposit Account	032095
Authorized User	Cristina Lofton
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: 37 CFR 1.21 (Miscellaneous fees and charges) 37 CFR 1.20 (Post Issuance fees)	

37 CFR 1.19 (Document supply fees)
 37 CFR 1.17 (Patent application and reexamination processing fees)
 37 CFR 1.16 (National application filing, search, and examination fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	50761-029001_-_Fee_Transmittal_-_Part_B_PTOL-85.pdf	36547	no	1
			7802388a0dc409ded46469e57f1a0c38f5ca2b50		

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	37978	no	2
			e49ed55cd0a5fc7ff177353ad53c048ca923647c		

Warnings:

Information:

Total Files Size (in bytes):	74525
-------------------------------------	-------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

AMENDMENT TO THE DRAWINGS

Please replace the drawing sheet containing FIG. 3A and FIG. 3B with the replacement sheet submitted herewith.

REMARKS

Applicant has provided a replacement sheet for the drawing sheet containing FIG. 3A and FIG. 3B.

No new matter has been added by the present amendments. Applicant reserves the right to pursue any cancelled subject matter in this or in a continuing application.

Please apply any charges or credits to Deposit Account No. 03-2095.

Dated: April 26, 2022

Respectfully submitted,

/Jan N. Tittel/

Jan N. Tittel, Ph.D.

Registration No.: 52,290

CLARK & ELBING LLP

101 Federal Street

15th Floor

Boston, MA 02110

(617) 428-0200



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/097,285	11/13/2020	Jean-Claude TARDIF	50761-029001	3015
21559 7590 04/26/2022 CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110			EXAMINER DAVIS, BRIAN J	
			ART UNIT 1612	PAPER NUMBER
			NOTIFICATION DATE 04/26/2022	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com
smmichaud@clarkelbing.com



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Application No. : 17097285
Applicant : Tardif
Filing Date : 11/13/2020
Date Mailed : 04/26/2022

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given two (2) months from the mail date of this Notice within which to respond. This time period for reply is extendable under 37 CFR 1.136(a) for only TWO additional MONTHS.

The informalities requiring correction are indicated in the attachment(s). If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to respond within the above-identified time period will result in the application being ABANDONED.

See attachment(s).

*A copy of this notice **MUST** be returned with the reply. Please address response to
"Mail Stop Issue Fee, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450".*

/Quang Nguyen/
Publication Branch
Office of Data Management
(571) 272-4200

IDENTIFICATION OF DRAWING DEFICIENCIES

- ☐ There is a hole or the image thereof within the illustration. FIG(s)
- ☐ The illustration is penetrated or traversed by a solid or broken line that is not intended to be part of the drawing, such as a dark line caused by a flaw in the copying process. FIG(s)
- ☐ An ink stamp or the image thereof obscures part of the illustration. FIG(s)
- ☐ The drawing is marred by black smudges, obliterations, or fax/copier marks (for example, speckles or dots in a substantial portion of the drawing). FIG(s)
- ☐ Figure numbers are duplicated or missing. FIG(s)
- ☐ Drawing sheet or figure is missing. FIG(s)
- ☐ Numbers, letters, or reference characters in the drawing have been crossed out or are illegibly handwritten. FIG(s)
- ☒ The character of the lines, numbers, and letters is poor. FIG(s) 3A-3B
- ☐ The drawing's background shows that the original drawing was made on graph paper or other paper with a pattern or decoration. FIG(s)
- ☐ The FIG. number label is placed in a location that causes the drawing to be read upside down. FIG(s)
- ☐ Data, a reference number, or part of the drawing is truncated or missing, or a lead line has no reference number. FIG(s)
- ☐ The drawing and/or the FIG. label contain(s) foreign language. FIG(s)
- ☐ This utility application contains a photograph of a view that is capable of being illustrated as a line drawing. FIG(s)
- ☐ A petition under 37 CFR 1.84(a)(2) to accept color drawings has been granted, but the brief description of the drawings in the specification does not contain (or has not been amended to contain) the paragraph required by 37 CFR 1.84(a)(2)(iii).
- ☐ This reissue application contains added and/or amended drawings that are not labeled as "New" or "Amended" or "Canceled" as required by 37 CFR 1.173(b)(3). FIG(s)
- ☐ This Design reissue application contains a drawing that is labeled as "Canceled" but is not surrounded by brackets, or a drawing that is surrounded by brackets but is not labeled as "Canceled." See 37 CFR 1.173(b)(3). FIG(s)
- ☐ OTHER:
- ☐ COMMENTS:



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/097,285	08/02/2022	11400063	50761-029001	3015
21559	7590	07/13/2022		
CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110				

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE), Stakeholder Support Division (SSD) at (571)-272-4200.

INVENTOR(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional inventors):

Jean-Claude TARDIF, Montreal, CANADA;

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

INSTITUT DE CARDIOLOGIE DE MONTREAL, Montreal, CANADA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

To: patentadministrator@clarkelbing.com,smmichaud@clarkelbing.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 21559

Jul 14, 2022 05:10:24 AM

Dear PAIR Customer:

CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 21559 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
17097285	ISSUE.NTF	07/13/2022	50761-029001

To view your correspondence online or update your email addresses, please visit us anytime at <https://portal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

Docket No.: 50761-029001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Jean-Claude TARDIF

Patent No.: 11,400,063

Issued: August 2, 2022

For: EARLY ADMINISTRATION OF LOW-DOSE
COLCHICINE AFTER MYOCARDIAL INFARCTION

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 C.F.R. § 1.322**

Applicants hereby request that a Certificate of Correction be issued in the patent identified above.
The errors to be corrected are described in detail on the enclosed Form PTO/SB/44.

No fee is believed to be due, as the errors to be corrected were made by the PTO. If there are any
charges or credits, please apply them to Deposit Account No. 03-2095.

Dated: September 13, 2022

Respectfully submitted,

/Jan N. Tittel/
Jan N. Tittel, Ph.D.
Registration No.: 52,290
CLARK & ELBING LLP
101 Federal Street
15th Floor
Boston, MA 02110
(617) 428-0200

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 11,400,063
APPLICATION NO. : 17/097,285
ISSUE DATE : August 2, 2022
INVENTOR(S) : Jean-Claude TARDIF

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 41, Line 50, replace "alter" with --after--.

Column 42, Line 30, replace "coichicine" with --colchicine--;
Line 38, replace "coichicine" with --colchicine--;
Line 51, replace "coichicine" with --colchicine--.

MAILING ADDRESS OF SENDER (Please do not use Customer Number below):

James D. DeCamp
CLARK & ELBING LLP
101 Federal Street
15th Floor
Boston, MA 02110

1

3567124



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #
17/097,285

RECEIPT DATE / TIME
09/13/2022 11:17:22 AM ET

ATTORNEY DOCKET #
50761-029001

Title of Invention

EARLY ADMINISTRATION OF LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 11400063

CONFIRMATION # 3015

FILED BY Ashley Lombardi

PATENT CENTER # 60961737

FILING DATE 11/13/2020

CUSTOMER # 21559

FIRST NAMED INVENTOR Jean-Claude TARDIF

CORRESPONDENCE ADDRESS -

AUTHORIZED BY Jan Tittel

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
COC_Request.pdf	2	Request for Certificate of Correction	77 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
COC_Request.pdf	0B2D86001301C84F7F8A3D539D5E141908CC3984800F04837B 8D33BFDB4A181E522DE2F64F534D480FA1EBC62217E158290 A2A40291A80FA1429B7F9BFF84BD4

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized

by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 11,400,063 B2
APPLICATION NO. : 17/097285
DATED : August 2, 2022
INVENTOR(S) : Jean-Claude Tardif

Page 1 of 1


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

Column 41, Line 50, replace "alter" with --after--.

Column 42, Line 30, replace "coichicine" with --colchicine--;
Line 38, replace "coichicine" with --colchicine--;
Line 51, replace "coichicine" with --colchicine--.

Signed and Sealed this
Twenty-fifth Day of October, 2022



Katherine Kelly Vidal
Director of the United States Patent and Trademark Office